Trial Profile
A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Bacteraemia; Gram-positive infections; Skin and soft tissue infections
- Focus Pharmacodynamics
- Sponsors Trius Therapeutics
- 12 Jun 2013 Results were published in Antimicrobial Agents and Chemotherapy, according to a Trius Therapeutics media release.
- 11 Sep 2012 Results will be presented at ICAAC-2012 according to a Trius Therapeutics media release.
- 13 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.